Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
2-deoxy-D-Glucose is a glucose antimetabolite and an inhibitor of glycolysis.1,2 It is metabolized by hexokinase into 2-deoxy-D-glucose-6-phosphate (2-DG6P), which cannot be metabolized by glucose-6-phosphate isomerase, leading to 2-DG6P accumulation, inhibition of glycolysis, and cell death.3 2-deoxy-D-glucose (16 mM) induces apoptosis in SK-BR-3 cells, as well as inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions when used at a concentration of 2 mg/ml.4,5 In vivo, 2-deoxy-D-glucose (500 mg/kg) reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin (Item No. 15007) or paclitaxel (Item No. 10461).6
WARNING This product is not for human or veterinary use.
1. 2-
2. Evaluation of 2-
3. 2-
4. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: A strategy for solid tumor therapy (Model C). Biochem. Pharmacol. 64(12), 1745-1751 (2002).
5. Effect of 2-
6. 2-
GOT1 inhibition primes pancreatic cancer for ferroptosis through the autophagic release of labile iron. bioRxiv (2020).
Regional metabolic analysis of structurally preserved kidney slices by ex vivo respirometry. Am. J. Physiol. Renal Physiol. 329(6), F796-F808 (2025).